KEYTRUDA

April 13, 2020April 13, 2020

Keytruda Prolongs Life Without Disease Worsening in Classical Hodgkin’s Lymphoma, Interim Data Confirm

News

Keytruda (pembrolizumab) significantly extends survival without disease worsening in adults with relapsed or refractory classical Hodgkin’s Lymphoma (cHL), compared to treatment with Adcetris (brentuximab vedotin), interim data from a Phase ... Read more

July 19, 2019July 19, 2019

Affimed Trial Updates Support AFM13 Use for Certain CD30-positive Lymphomas

News

Updated results from two clinical trials support the potential of AFM13, an investigational immunotherapy being developed by Affimed, in combination with Merck‘s Keytruda (pembrolizumab) for patients with Hodgkin’s lymphoma, or ... Read more

November 5, 2018

MK-1454/Keytruda Combination Shows Promise in Solid Tumor and Lymphoma Patients

News

A combination of the investigational agent MK-1454 and Keytruda (pembrolizumab) induced robust and durable responses in solid tumor and lymphoma patients in a Phase 1 trial, Merck (known as MSD outside the ... Read more

June 27, 2018

Keytruda-AFM13 Combo Effective for Hodgkin’s Lymphoma, Preliminary Phase 1b Data Show

News

Treatment with Keytruda (pembrolizumab) and Affimed’s AFM13 is well-tolerated with a favorable response rate in patients with relapsed or refractory Hodgkin’s lymphoma, according to an early analysis of a Phase 1b trial. ... Read more

June 20, 2018

Keytruda Conditionally Approved in US for Primary Mediastinal B-cell Lymphoma

News

The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), making it the first anti-PD-1 therapy ... Read more

June 12, 2018

Xynomic Pharma Plans 4 Clinical Trials of Abexinostat for Lymphoma

News

Xynomic Pharma announced it has completed a new Series B financing round and now will initiate eight clinical trials, four of which are for different types of lymphoma, in the next 12 ... Read more

June 4, 2018

Alexo Begins Testing ALX148 Combinations in Phase 1 Trial of NHL, Solid Tumors

News

Alexo Therapeutics has started treating patients in the combination part of its Phase 1 trial, which will test multiple combinations of ALX148 with targeted antibody therapies — including Keytruda (pembrolizumab), Herceptin ... Read more

April 3, 2018

Phase 2 Study of DPX-Survivac Combo Doses First Lymphoma Patient

News

A Phase 2 trial testing Immunovaccine‘s combination of DPX-Survivac with chemotherapy and an immune checkpoint inhibitor in diffuse large B-cell lymphoma (DLBCL) has dosed its first participant. The trial is supported by Merck ... Read more

March 14, 2018March 14, 2018

G100-Keytruda Combo Shows Higher Response in Follicular Lymphoma Patients in Phase 2 Trial

News

Data from a Phase 2 clinical trial showed that combining Immune Design‘s experimental immunotherapy G100 with fractioned, low-dose radiation and Keytruda (pembrolizumab) leads to higher response rates in follicular lymphoma patients, the company announced. The randomized ... Read more

February 5, 2018February 5, 2018

Affimed’s AFM13 Shows High Response Rates in 2 Lymphoma Subtypes

News

AFM13, a bispecific antibody that recruits natural killer (NK) cells to the vicinity of a tumor, has shown promise in clinical trials of both Hodgkin’s lymphoma and in CD30-positive cutaneous ... Read more